Melanoma
is a type of skin cancer that develops from the pigment cells known
as melanocytes. It is caused due to high exposure to ultraviolet
rays, which leads to sunburn, especially at high altitudes. Melanoma
is categorized into three: cutaneous, mucosal, and ocular. Cutaneous
affects the skin, mucosal affects the mucous membrane in the mouth
and nasal passage, and ocular affects the eye. However, early
detection of melanoma helps in the treatment and increase survival
rates. According to the American Academy of Dermatology 2015 report,
the prevalence of melanoma is increasing and spreads to other body
parts as well. As it spreads to other body parts, its treatment
becomes much more complex. The rare genetic conditions such as
xeroderma pigmentosum also increase the risk of melanoma and it is
diagnosed with the biopsy of any skin lesion.
Ask
for Sample Copy of Research @
https://www.coherentmarketinsights.com/insight/request-sample/719
Development
of new drugs fuels the melanoma treatment market
Several
drugs in the market have already received FDA approval for melanoma
treatment and some are under development. Drugs such as
seviprotimut-L by Polynoma’s, talimogene laherparepvec (T-VEC) by
Amgen Inc., and zelboraf, by Roche and Genetech together for the
treatment of cutaneous melanoma are under development. Selumetinib is
under development by AstraZeneca for the treatment of ocular
melanoma. In 2011, Yervoy, a monoclonal antibody drug was developed
by Bristol-Myers Squibb for the treatment of melanoma and it is the
first drug to receive FDA approval. Immunotherapy drugs include
opdivo and keytruda, which got FDA approval and created new
opportunities in melanoma treatment market. When chemotherapy fails
to deliver results, targeted therapy is used, which include BRAF
inhibitors. Targeted therapy has limited side effects in comparison
with chemotherapy.
Developed
regions support the growth of melanoma treatment market
Melanoma
treatment market, based on geography, is segmented into North
America, Latin America, Europe, Asia Pacific, and Middle East &
Africa. North America dominates the melanoma treatment market due to
the high prevalence of melanoma in the region along with
well-developed healthcare facilities and increased research and
development on melanoma drugs. Moreover, reimbursement policy and
increase in per capita income are expected to fuel the melanoma
treatment market. Europe is the second largest market and is expected
to grow significantly in near future due to increase in melanoma
cases and development of novel therapies. Asia Pacific is expected to
exhibit moderate growth due to fewer cases of skin cancer, lack of
awareness, and high cost of melanoma drugs.
Key
Players in the Global Melanoma Treatment Market
Some
of the key players identified across the value chain of global
melanoma treatment market are Bristol-Myers Squibb, F. Hoffmann-La
Roche Ltd., Genetech Inc., Novartis AG, Polynoma LLC, AstraZeneca,
Amgen Inc., Sanofi, Merck & Co. Inc., and Takeda Pharmaceutical
Company.
Melanoma
Treatment Market Taxonomy:
The
global melanoma treatment market is segmented as follows;
By
Melanoma Type;
-
Cutaneous Melanoma
-
Mucosal Melanoma
-
Ocular Melanoma
By
Therapy;
-
Chemotherapy
-
Immunotherapy
-
Targeted Therapy
-
Surgical Treatment
-
Pharmacological Treatment
Find
the comprehensive research report here with a single click:
https://www.coherentmarketinsights.com/ongoing-insight/melanoma-treatment-market-719
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment